OCGN - Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value

2024-04-19 17:05:07 ET

Summary

• Ocugen, Inc. expects preliminary safety/efficacy data from phase 1/2 study, using OCU-410 for the treatment of patients with GA, in 2024.
• Preliminary safety/efficacy data from phase 1/2 study, using OCU-401ST for the treatment of patients with Stargardt Disease, expected in 2024.
• OCU-400 is being advanced to treat patients with Retinitis Pigmentosa in a phase 3 study; With positive data it expects to file an NDA of OCU-400 in 2026.
• In a prior study, it was stated that 83% of Retinitis Pigmentosa patients achieved disease stabilization or improvement after a single subretinal dose of OCU-400.

Ocugen, Inc. ( OCGN ) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being advanced in phase 1/2 studies for the treatment of patients with Geographic Atrophy [GA], and Stargardt Disease, respectively. Preliminary data readouts from both of these studies are expected to be released in 2024....

For further details see: